Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Synlogic

Synlogic

A company developing therapeutic probiotics that alter the human gut microbiome to treat diseases.

Synologic is a clinical-stage biopharmaceutical company developing living medicines to treat a range of metabolic diseases, inflammatory diseases, and cancers. The technology platform uses synthetic biology to engineer beneficial bacteria, or probiotics, that alter the composition of the gut microbiome to restore proper metabolic functions. The populations of bacteria comprising the gut microbiome play a critical role in regulating the human immune system, metabolic function, brain health, and more. The company was founded in 2007 and is headquartered in Boston, Massachusetts.

Clinical programs

The majority of the company's drug candidates are in pre-clinical testing, although its lead drug candidate is in phase 2 trials. Synlogic calls its probiotics Synthetic Biotics. The pipeline as of July, 2nd, 2018:

Disease Targeted
Stage of Development
Partner

Hepatic encephalopathy

Phase 2

None

Immune oncology (three programs)

Pre-clinical

None

Inflammatory bowel disease

Pre-clinical

Liver disease

Screening

None

Maple Syrup urine disease

Pre-clinical

None

Partnerships
AbbVie
Ginkgo Bioworks

In December 2017 Synlogic and Ginkgo Bioworks announced a collaboration to use the latter's industrial scale organism engineering platform to discover new drug candidates.

Mergers and Acquisitions

In May 2017 Synlogic entered into a merger agreement with Mirna Therapeutics under which Synlogic merged with a wholly owned subsidiary of Mirna in an all-stock transaction. The merged company continued under the Synlogic name.

Timeline

June 17, 2021
Synlogic announces that it has entered into a research collaboration agreement with Roche.
March 8, 2021
Synlogic announces promotion of Dr. Caroline Kurtz to Chief Development Officer.
June 1, 2020
Synlogic, Inc. announces the publication in Nature Communications of preclinical data supporting its first clinical Immuno-oncology program.
June 2019
Synlogic raises a $80,000,000 venture round from Ginkgo Bioworks.
May 2017
Synlogic raises a $42,000,000 series C round from Ally Bridge Group, Arctic Aurora LifeScience, Atlas Venture, CLI Ventures, Daphne Teo, Deerfield Management Company, New Enterprise Associates, OrbiMed, Perceptive Advisors and Rock Springs Capital.
February 2016
Synlogic raises a $40,000,000 series B round from OrbiMed.
October 2014
Synlogic raises a $5,000,000 series A round from Atlas Venture and Bill & Melinda Gates Foundation.
July 2014
Synlogic raises a $29,400,000 series A round from Atlas Venture and New Enterprise Associates.
2014
Synlogic was founded by Alison Silva, Ankit Mahadevia, Dean Falb, James Collins and Timothy Lu.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Antonio Regalado
August 24, 2021
MIT Technology Review
Jason Kelly has promised a manufacturing revolution with DNA. Just don't ask him to make any products.
Synlogic, Inc.
June 17, 2021
www.prnewswire.com:443
/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today...
BioSpace
June 15, 2021
BioSpace
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the development of the investigational Synthetic Biotic medicineTM SYNB8802 for the treatment of Enteric Hyperoxaluria and on SYNB1934,
Synlogic, Inc.
June 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented...
Synlogic, Inc.
May 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced...
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.